医薬品受託開発・製造の市場規模・シェア・成長分析 (サービス別、エンドユーザー別、地域別)：産業予測 (2025～2032年)

世界の医薬品受託開発・製造の市場規模は2023年に1,222億米ドルとなり、2024年の1,306億3,000万米ドルから2032年には2,227億8,000万米ドルに成長し、予測期間 (2025年～2032年) のCAGRは6.9%で推移する見通しです。

医薬品受託開発・製造市場は、先端技術の採用拡大、特許満了、研究開発投資の活発化など、複数の要因によって力強い成長を遂げています。COVID-19の大流行が拍車をかけたジェネリック医薬品と生物製剤の需要が、この拡大をさらに後押ししています。また、細胞・遺伝子治療、オーダーメイド医薬品、高活性医薬品成分 (HPAPI)、抗体薬物複合体 (ADC) に対するニーズの高まりも、市場の成長を後押ししています。しかし、シリアル化の導入や適格な専門家の不足といった課題が、進展の妨げになる可能性があります。今後、企業は、新たな機会を活用し、この進化する情勢の中で成長を維持するために、これらの力学をうまく利用しなければなりません。

目次

イントロダクション

• 分析目的
• 市場範囲
• 定義

分析手法

• 情報調達
• 二次・一次データの手法
• 市場規模予測
• 市場の想定と制約

エグゼクティブサマリー

• 市場の概要と展望
• 需給動向の分析
• セグメント別の機会分析

市場力学と展望

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーター分析

市場の主な考察

• 主な成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場魅力度指数 (2024年)
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 技術分析
• 規制分析
• ケーススタディ

世界の医薬品受託開発・製造の市場規模・CAGR：サービス別 (2025～2032年)

• 市場概要
• 医薬品製造サービス
  • API製造サービス
  • FDF製造サービス
• 医薬品開発サービス
• バイオ医薬品製造サービス
  • API製造サービス
  • FDF製造サービス
• 梱包サービス

世界の医薬品受託開発・製造の市場規模・CAGR：エンドユーザー別 (2025～2032年)

• 市場概要
• 大手製薬企業
• 中小製薬企業
• ジェネリック医薬品企業
• その他

世界の医薬品受託開発・製造の市場規模・CAGR (2025～2032年)

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング (2024年)
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析 (2024年)
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較 (2022-2024)

主要企業プロファイル

• Cambrex Corporation
• Samsung Biologics Co., Ltd.
• Siegfried Holdings AG
• FUJIFILM Diosynth Biotechnologies
• Aenova Group
• Wuxi Biologics, Inc.
• Aurobindo Pharma, Ltd.
• Vetter Pharma International GmbH
• Thermo Fisher Scientific, Inc.
• Catalent, Inc
• Recipharm AB
• Almac Group
• Lonza Group Ltd.
• Piramal Enterprises Limited
• Fabbrica Italiana Sintetici S.p.A.
• Fareva SA
• C.H. Boehringer Sohn AG & Co. KG.
• Jubilant Pharmova Limited
• Curia Global, Inc.
• Delpharm Holdings

結論と推奨事項

Global Pharmaceutical Contract Development and Manufacturing Market size was valued at USD 122.2 billion in 2023 and is poised to grow from USD 130.63 billion in 2024 to USD 222.78 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

The pharmaceutical contract development and manufacturing market is experiencing robust growth driven by multiple factors, including the increasing adoption of advanced technologies, patent expirations, and heightened investments in research and development. Demand for generic medications and biologics, spurred by the COVID-19 pandemic, further fuels this expansion. The market is also poised for growth due to the rising need for cell and gene therapies, customized medicines, high potency active pharmaceutical ingredients (HPAPIs), and antibody-drug conjugates (ADCs). However, challenges such as the implementation of serialization and a shortage of qualified professionals may hinder progress. Moving forward, firms must navigate these dynamics to capitalize on emerging opportunities and sustain growth in this evolving landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pharmaceutical Contract Development And Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pharmaceutical Contract Development And Manufacturing Market Segmental Analysis

Global Pharmaceutical Contract Development and Manufacturing Market is segmented by Service, End User and region. Based on Service, the market is segmented into Pharmaceutical Manufacturing Services, Drug Development Services, Biologics Manufacturing Services and Packaging Services. Based on End User, the market is segmented into Large Pharmaceutical Companies, Small and Mid-size Pharmaceutical Companies, Generic Pharmaceutical Companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pharmaceutical Contract Development And Manufacturing Market

The Global Pharmaceutical Contract Development and Manufacturing market is experiencing significant growth due to the rising demand for pharmaceuticals targeting chronic illnesses. This demand is further bolstered by the numerous benefits of outsourcing, particularly in terms of cost and time efficiency. Companies in this sector are investing heavily in enhancing their infrastructure, workforce, and technological capabilities to capture a larger portion of the outsourcing market. This trend underscores the shift towards outsourcing as a strategic move for pharmaceutical firms looking to streamline operations and optimize resources, thus driving the overall expansion of the contract development and manufacturing landscape.

Restraints in the Global Pharmaceutical Contract Development And Manufacturing Market

The Global Pharmaceutical Contract Development and Manufacturing market faces significant restraints, particularly due to a shortage of skilled labor, which threatens to impede market growth. Inadequate understanding of production processes can lead to defective product lines, thereby eroding consumer trust. This lack of confidence poses a risk not only to the relationships among developers, manufacturers, and distributors but also to the overall integrity of the market. As a result, addressing workforce shortages and enhancing process knowledge are crucial to mitigate the potential negative impacts and ensure a reliable and effective contract development and manufacturing ecosystem in the pharmaceutical industry.

Market Trends of the Global Pharmaceutical Contract Development And Manufacturing Market

The Global Pharmaceutical Contract Development and Manufacturing market is experiencing significant growth, driven primarily by the rising incidence of cancer and advancements in technology that facilitate the development of safe and effective medications. This trend underscores a burgeoning demand for oncology treatments, leading to a heightened focus on highly potent New Chemical Entities (NCEs). As researchers and manufacturers prioritize the creation of selective compounds that optimize therapeutic efficacy while minimizing dosing frequencies, Contract Development and Manufacturing Organizations (CDMOs) are increasingly leveraged to expedite the drug development process, aligning with the industry's shift towards personalized medicine and targeted therapies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Case Studies

Global Pharmaceutical Contract Development and Manufacturing Market Size by Service & CAGR (2025-2032)

• Market Overview
• Pharmaceutical Manufacturing Services
  • API Manufacturing Services
  • FDF Manufacturing Services
• Drug Development Services
• Biologics Manufacturing Services
  • API Manufacturing Services
  • FDF Manufacturing Services
• Packaging Services

Global Pharmaceutical Contract Development and Manufacturing Market Size by End User & CAGR (2025-2032)

• Market Overview
• Large Pharmaceutical Companies
• Small and Mid-size Pharmaceutical Companies
• Generic Pharmaceutical Companies
• Others

Global Pharmaceutical Contract Development and Manufacturing Market Size & CAGR (2025-2032)

• North America (Service, End User)
  • US
  • Canada
• Europe (Service, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Service, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Service, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Service, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Cambrex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siegfried Holdings AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FUJIFILM Diosynth Biotechnologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aenova Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wuxi Biologics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma, Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetter Pharma International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent, Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recipharm AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Almac Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal Enterprises Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fabbrica Italiana Sintetici S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fareva SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• C.H. Boehringer Sohn AG & Co. KG.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Pharmova Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curia Global, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Delpharm Holdings
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations